Katharine Ellwood-Yen
Overview
Explore the profile of Katharine Ellwood-Yen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
894
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Majumder P, Grisanzio C, OConnell F, Barry M, Brito J, Xu Q, et al.
Cancer Cell
. 2024 Jun;
42(6):1126.
PMID: 38866454
No abstract available.
2.
Ellwood-Yen K, Keilhack H, Kunii K, Dolinski B, Connor Y, Hu K, et al.
Cancer Res
. 2011 Apr;
71(8):3052-65.
PMID: 21493594
PDK1 activates AKT suggesting that PDK1 inhibition might suppress tumor development. However, while PDK1 has been investigated intensively as an oncology target, selective inhibitors suitable for in vivo studies have...
3.
Clegg N, Couto S, Wongvipat J, Hieronymus H, Carver B, Taylor B, et al.
PLoS One
. 2011 Mar;
6(3):e17449.
PMID: 21394210
MYC and phosphoinositide 3-kinase (PI3K)-pathway deregulation are common in human prostate cancer. Through examination of 194 human prostate tumors, we observed statistically significant co-occurrence of MYC amplification and PI3K-pathway alteration,...
4.
Nandana S, Ellwood-Yen K, Sawyers C, Wills M, Weidow B, Case T, et al.
Prostate
. 2009 Nov;
70(6):591-600.
PMID: 19938013
Background: Hepsin is a cell surface protease that is over-expressed in more than 90% of human prostate cancer cases. The previously developed Probasin-hepsin/Large Probasin-T antigen (PB-hepsin/LPB-Tag) bigenic mouse model of...
5.
Jin R, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, et al.
Cancer Res
. 2008 Aug;
68(16):6762-9.
PMID: 18701501
Typically, the initial response of a prostate cancer patient to androgen ablation therapy is regression of the disease. However, the tumor will progress to an "androgen-independent" stage that results in...
6.
Majumder P, Grisanzio C, OConnell F, Barry M, Brito J, Xu Q, et al.
Cancer Cell
. 2008 Aug;
14(2):146-55.
PMID: 18691549
Transgenic expression of activated AKT1 in the murine prostate induces prostatic intraepithelial neoplasia (PIN) that does not progress to invasive prostate cancer (CaP). In luminal epithelial cells of Akt-driven PIN,...
7.
Ellwood-Yen K, Wongvipat J, Sawyers C
Cancer Res
. 2006 Nov;
66(21):10513-6.
PMID: 17079473
Persistent androgen receptor signaling has been implicated as a critical factor in prostate cancer progression even at the hormone-refractory stage and provides strong rationale for developing novel androgen receptor antagonists....
8.
Watson P, Ellwood-Yen K, King J, Wongvipat J, LeBeau M, Sawyers C
Cancer Res
. 2005 Dec;
65(24):11565-71.
PMID: 16357166
Insights into the molecular basis of hormone-refractory prostate cancer have principally relied on human prostate cancer cell lines, all of which were derived from patients who had already failed hormonal...
9.
Ellwood-Yen K, Graeber T, Wongvipat J, Iruela-Arispe M, Zhang J, Matusik R, et al.
Cancer Cell
. 2003 Oct;
4(3):223-38.
PMID: 14522256
Increased Myc gene copy number is observed in human prostate cancer. To define Myc's functional role, we generated transgenic mice expressing human c-Myc in the mouse prostate. All mice developed...
10.
Gorre M, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers C
Blood
. 2002 Sep;
100(8):3041-4.
PMID: 12351420
Clinical resistance to imatinib mesylate is commonly observed in patients with advanced Philadelphia chromosome- positive (Ph(+)) leukemias. Acquired resistance is typically associated with reactivation of BCR-ABL due to kinase domain...